{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:40:51Z","timestamp":1769913651694,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.advms.2016.07.002","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T15:46:53Z","timestamp":1487087213000},"page":"92-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease \u2013 specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires"],"prefix":"10.1016","volume":"62","author":[{"given":"Agnieszka","family":"Kalinska-Bienias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Jakubowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cezary","family":"Kowalewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.advms.2016.07.002_bib0115","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1038\/jid.2014.171","article-title":"From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseases","volume":"134","author":"Ludwig","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.advms.2016.07.002_bib0120","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clindermatol.2011.03.016","article-title":"Quality of life in patients with bullous dermatoses","volume":"30","author":"Sebaratnam","year":"2012","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.advms.2016.07.002_bib0125","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.det.2011.03.009","article-title":"Pemphigus and quality of life","volume":"29","author":"Chee","year":"2011","journal-title":"Dermatol Clin"},{"issue":"6","key":"10.1016\/j.advms.2016.07.002_bib0130","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1365-2230.2011.04282.x","article-title":"Quality of life in patients with pemphigus receiving adjuvant therapy","volume":"37","author":"Paradisi","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.advms.2016.07.002_bib0135","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1365-2133.2008.08481.x","article-title":"The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the Medical Outcomes Study 36-item short form health survey questionnaire","volume":"158","author":"Tabolli","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.advms.2016.07.002_bib0140","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0151-9638(05)79276-0","article-title":"Quality of life and pemphigus","volume":"132","author":"Terrab","year":"2005","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.advms.2016.07.002_bib0145","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1346-8138.2011.01382.x","article-title":"Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires","volume":"39","author":"Ghodsi","year":"2012","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.advms.2016.07.002_bib0150","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1087-0024.2004.09113.x","article-title":"10 years experience of the Dermatology Life Quality Index (DLQI)","volume":"9","author":"Lewis","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"2","key":"10.1016\/j.advms.2016.07.002_bib0155","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1590\/abd1806-4841.20153372","volume":"90","author":"Penha","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"10","key":"10.1016\/j.advms.2016.07.002_bib0160","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamadermatol.2013.4972","article-title":"Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire","volume":"149","author":"Sebaratnam","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.advms.2016.07.002_bib0165","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/bjd.12623","article-title":"The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease","volume":"169","author":"Tjokrowidjaja","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.advms.2016.07.002_bib0170","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/1346-8138.12711","article-title":"Outcome measures for autoimmune blistering diseases","volume":"42","author":"Zhao","year":"2015","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.advms.2016.07.002_bib0175","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2133.1971.tb14190.x","article-title":"Correlation of pemphigoid and pemphigus antibody titres with activity of disease","volume":"84","author":"Sams","year":"1971","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.advms.2016.07.002_bib0180","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/archderm.139.8.1007","article-title":"A practical technique for differentiation of subepidermal bullous diseases: localization of in vivo-bound IgG by laser scanning confocal microscopy","volume":"139","author":"Wozniak","year":"2003","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.advms.2016.07.002_bib0185","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2007.00292.x","article-title":"Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials","volume":"11","author":"Acquadro","year":"2008","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.advms.2016.07.002_bib0190","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jaad.2013.04.053","article-title":"Measuring quality of life in epidermolysis bullosa in Mexico: cross-cultural validation of the Hispanic version of the Quality of Life in Epidermolysis Bullosa questionnaire","volume":"69","author":"Frew","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.advms.2016.07.002_bib0195","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.det.2011.03.015","article-title":"Objective scoring systems for disease activity in autoimmune bullous disease","volume":"29","author":"Sebaratnam","year":"2011","journal-title":"Dermatol Clin"},{"issue":"9","key":"10.1016\/j.advms.2016.07.002_bib0200","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s11136-015-0965-z","article-title":"Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA","volume":"24","author":"Sebaratnam","year":"2015","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.advms.2016.07.002_bib0205","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age","volume":"138","author":"Rzany","year":"2002","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.advms.2016.07.002_bib0210","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1610-0387.2005.05722.x","article-title":"Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group","volume":"3","author":"Mayrshofer","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.advms.2016.07.002_bib0215","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jaad.2008.09.014","article-title":"Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools","volume":"60","author":"Paradisi","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.advms.2016.07.002_bib0220","first-page":"283","article-title":"An investigation of quality of life (QOL) of pemphigus patients in Japan (first report)","volume":"110","author":"Masahiro","year":"2000","journal-title":"J Dermatol"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112616300384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112616300384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T09:29:42Z","timestamp":1536053382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112616300384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1896112616300384"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2016.07.002","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease \u2013 specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2016.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Medical University of Bialystok. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}